Provide consulting services to companies involved in oncology drug discovery, translation, and early development. Clients include startups, biotech, and large pharma.

Build research lab capabilities and provide and execute strategic plan for start up.Crux advanced two novel programs to the drug lead stage with minimal funding.

Molecular Response offers fully-integrated solutions for the discovery and application of molecular markers that are predictive of patient response in clinical trials. Acquired by BioDuro.-Provide advice, oversight, and execution for a variety of molecular assays to further the shared goals of advancing personalized medicine in oncology.-Catalyze the development of a comprehensive database of patient-derived xenograft models.-Evaluate a novel oncology drug target.-Supervise lab members on selected projects, particularly regarding molecular biology.

Highly productive year as contracted employee, which ended when Biogen Idec discontinued oncology drug discovery and closed the San Diego site.Evaluation of the MOA of a late clinical stage monoclonal antibody based on a new understanding of the target biology; implications for greatly expanding the cancer indications by modulating effects on the tumor microenvironment.Further elucidation of the MOA of a preclinical stage antibody targeting a member of the TNF receptor superfamily.Identified new targets for discovery and/or in-licensing opportunities.Chapman MS, Wu L, Amatucci A, Ho SN, Michaelson JS (2013) "TWEAK signals through JAK-STAT to induce tumor cell apoptosis" Cytokine 61:210-217.

Discovery and validation of synergistic combinations of a MEK inhibitor with other anti-cancer agents, as well as translational aspects of this kinase inhibitor during Phase 1 and Phase1/2 clinical trials, contributing to the partnering of RDEA119 to Bayer (Now BAY86-9766). Further work included early discovery and target validation. Initiating and managing collaborations with CROs, academic groups, and clinicians.My collaborative research at Ardea Biosciences contributed to RDEA119 partnering ($400M+) and several ongoing combination trials.Highly Productive:Chapman MS and Miner JN (2011) “Novel mitogen-activated protein kinase kinase inhibitors.” Expert Opin. Investig. Drugs 20 (2):209-220.Chang Q, Chapman MS, Miner JN, Hedley DW. (2010) “Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.” BMC Cancer.;10:515.“COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF”, (Ardea BioSciences, 2008, PCT/US2008/071397).“TREATMENT OF PANCREATIC CANCER” (Ardea Biosciences, 2010, PCT/US2010/027021).

Research Investigator (2006-2008)Senior Research Scientist (2003-2006)Research Scientist (2000-2003)Project Team Leader: Advanced Prostate CancerServed as team leader for a novel drug discovery effort targeting advanced prostate cancer via degradation of the androgen receptor. Project involved up to 28 FTEs, including members from all research departments. Led all aspects of the program, including budget, day-to-day progress, decisions on advancement of compounds, and overall strategic direction. Assay Development and Compound CharacterizationDeveloped novel cell-based and in vivo assays for identifying compounds that act as selective androgen receptor ligands, resulting in the IND nomination of multiple SARM compounds with reduced side effects on prostate. Developed cell-based assays for cytokine mimetic drug discovery and characterization, contributing to LGD4665, a backup for the small molecule thrombopoietin mimetic eltrombopag. Used microarray technology to discover novel targets for assay development and drug discovery, as well as to understand late preclinical observations. Supported efforts to expand indications for denileukin diftitox. Directly supervised bench scientistsHong, MH, et al (2008) “Cell-specific activation of the human skeletal {alpha}-actin by androgens.” Endocrinology. 149(3):1103-12.Miner JN, et al. (2007) “An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate.” Endocrinology. 148(1):363-73.Schaufele F et al. (2005) “The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions.” PNAS.;102(28):9802-7.Chapman, M. S., et al. (2004) “Searching for SARA: The Role of Selective Androgen Receptor Antagonists in Prostate Cancer”, in Promising Cancer Chemopreventive Agents; G. Kelloff and C. Sigman, eds. Humana Press, Inc.